1. No category

For a richer research landscape in Leiden
Reversible immortalization method for generation of
homogenous, stable & authentic human cell lines
Key benefits
• Allows generation of LARGE,
HOMOGENOUS, STABLE and
AUTHENTIC populations of
differentiated cells.
• EASY control of cell proliferation
and differentiation.
Market sectors: Pharmaceutical industry, Biotech/medical companies
Researchers of the Leiden University Medical Center have
discovered a broadly applicable immortalization method for
mammalian (including human) cells, allowing expansion and
redifferentation of your cell type of choice through gene
transfer and simple changes in culture medium
composition.
One way to obtain large numbers of differentiated cells from small tissue
samples (i.e. biopsies) is by permanently immortalizing the cells directly
after isolation followed by their expansion in a dedifferentiated state and
their redifferentiation using specific medium formulations. This, however,
rarely yields cells in an advanced state of differentiation (i.e. authentic cells)
due to the continued presence of proliferation stimuli.
This invention concerns the discovery of a new immortalization technique
that overcomes many of the shortcomings of the existing immortalization
strategies and allows the reproducible generation of large numbers of
differentiated cells with very similar properties as the cells from which they
have been derived. These differentiated cells may provide a superior
alternative for cell-based systems relying on differentiation of, for instance,
pluripotent (human) stem cells and could therefore become the PLATINUM
STANDARD for cellular model systems (e.g. for drug testing) & production
platforms (e.g. for 3D tissue printing or to produce biopharmaceuticals).
• Applicable to ALL kinds of avian
and mammalian cells.
• Can be used to derive TISSUE-,
PATIENT- and DISEASE-SPECIFIC
cell platforms.
Applications
• See picture.
Development stage
• Proof-of-concept obtained for
atrial CARDIOMYOCYTES, cardiac
fibroblasts and epicardial
mesothelial cells.
Patent status
• In preparation.
Data available on request
• Confidential presentations.
Further information
Aletta Debernardi
Knowledge Broker
Email: : [email protected]
Telephone: + 31-(0)71-526 5575
Our ref#: INV-15MC450
Luris
Poortgebouw Noord
Rijnsburgerweg 10
2333 AA Leiden, The Netherlands
www.luris.nl